Novo Nordisk Seeks Approval for Breakthrough Higher-Dose Wegovy, Promising Enhanced Weight Loss

Healthcare Shorts Take a Breather, But Moderna Remains Under the Microscope

Employers Brace for Historic Health Plan Cost Surge in 2024

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

Legal Setback: Eli Lilly's Appeal Fails, $1.8 Billion Medicaid Fraud Award Upheld

Controversial Critic Returns: Dr. Vinay Prasad Reassumes Key FDA Role

The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

The Cost-Benefit Revolution: GLP-1 Drugs Deemed Value-Packed, But Price Tags Loom Large

Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave

Global Health Titans Act: FDA Tightens Grip on Safe Weight-Loss Meds as WHO Elevates Them to Essential Status

Jim Cramer's Ultimate Stock Market Draft: Nvidia & Eli Lilly Crowned Top Picks

A New Horizon in Lung Cancer Treatment: FDA Grants Breakthrough Status to Lilly-Merck Combination Therapy

Wegovy Triumphs: Novo Nordisk's Obesity Drug Significantly Cuts Heart Attack and Stroke Risk, Setting a New Benchmark in Cardiovascular Protection

Unearthing Tomorrow's Titans: Two Beaten-Down Growth Stocks Primed for Explosive Gains

Prothena's PRX012 Alzheimer's Drug Shines with 'Non-Competitive' Brain Swelling Rates, Offering New Hope

UK Healthcare on Edge: Mounjaro Shortages Loom as Eli Lilly's Price Hike Sparks Patient Panic

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

First RSV shots, groundbreaking gene therapy among 2024 drugs to watch

Weight loss drugs not linked to suicidal thoughts FDA